Skip to main content
Premium Trial:

Request an Annual Quote

Ideaya Biosciences, Broad Institute Partner on Synthetic Lethality-Based Cancer Drug Discovery

NEW YORK – Ideaya Biosciences on Thursday announced that it had partnered with the Sellers Laboratory at the Broad Institute of MIT and Harvard to generate target and biomarker discoveries for the treatment of patients with ovarian and breast cancers.

Specifically, the partnership will advance Ideaya's synthetic lethality-based approach to developing small molecule inhibitors against cancer targets. Synthetic lethality, which the company says represents an emerging class of precision medicine targets, refers to the loss of function of two genes that contribute to cancer cell death together, but would not do so on their own.

To help Ideaya achieve these synthetic lethality-based discoveries, the Broad Institute's Sellers Lab will bring to the partnership its CRISPR paralog screening platform, which will be used to evaluate functionally redundant paralogous genes across subtypes of ovarian cancer. Identifying these paralogous genes, in turn, will allow Ideaya to home in on synthetic lethality-based targets and biomarkers.

The collaboration will also specifically inform patient selection for Ideaya's existing synthetic lethality program targeting PARG. The Broad Institute will evaluate paralog CRISPR knockdown in selected cell lines treated with PARG inhibitors to better identify which breast and ovarian cancer patients may benefit from PARG-inhibiting treatment.

Additionally, Ideaya has joined the Broad Institute's Cancer Dependency Map (DepMap) consortium, which Ideaya says will enhance its bioinformatics and cell-based screening efforts for its synthetic lethality programs.

"Our lab has developed large-scale screening approaches to identify and validate novel synthetic lethal interactions," William Sellers, leader of the Broad Institute's Sellers Lab and member of Ideaya's scientific advisory board said in a statement. "We look forward to collaborating with Ideaya to translate this research for the discovery of potential patient-selection biomarkers and cancer therapeutics."

Beyond its collaboration with the Broad Institute, Ideaya has also recently collaborated with the University of California San Diego to advance its synthetic lethality discovery programs. For three such programs in development, Ideaya has entered a strategic partnership with GlaxoSmithKline. Other programs, however, including the PARG-targeting program, remain wholly owned by Ideaya.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.